IC0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Cash-generation ReboundA return to positive free cash flow in 2025 signals improved operational discipline and working-capital management. Durable cash generation reduces dependence on external financing, supports reinvestment or deleveraging, and materially lowers liquidity risk if the trend persists over multiple quarters.
Manageable LeverageA sub-0.5 debt-to-equity ratio provides financial flexibility for a growth or restructuring path. Improved leverage cuts interest burden and preserves borrowing capacity, enabling the company to fund capex or strategic initiatives without immediate equity dilution if profitability recovery continues.
Vertically Integrated ModelOwning cultivation through retail creates control over supply, quality and margin capture. Vertical integration supports product development, branded commercialization and channel diversification, which are structural advantages for sustained market share and resilience against single-channel disruptions.
Bears Say
Persistent LossesThree consecutive years of negative ROE and ongoing net losses indicate the company is not yet generating returns on invested capital. This erodes shareholder equity over time, limits reinvestment capacity, and raises the bar for management to deliver a sustained, structural profit turnaround.
Compressed MarginsMaterial gross margin compression undermines core profitability and suggests either pricing pressure, higher input costs, or unfavorable mix. Without margin restoration, top-line growth is less able to translate into sustainable earnings, weakening long-term free-cash-flow prospects.
Cash-flow VolatilityA sharp swing from large outflows to positive FCF highlights volatility in cash conversion. Such volatility raises execution risk: if working-capital or pricing dynamics revert, the company may face renewed funding needs or margin stress, impairing the durability of the 2025 improvement.
Intercure News
IC0 FAQ
What was InterCure’s price range in the past 12 months?
Currently, no data Available
What is InterCure’s market cap?
InterCure’s market cap is €48.87M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 31 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -€0.184 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.184.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Undervalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
Currently, no data Available
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -€0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in DE:IC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.